Equity Overview
Price & Market Data
Price: $270.1
Daily Change: +$6.07 / 2.25%
Daily Range: $265.0 - $270.1
Market Cap: $7,770,742,272
Daily Volume: 1,542
Performance Metrics
1 Week: 6.90%
1 Month: 4.06%
3 Months: 7.88%
6 Months: 43.97%
1 Year: 59.02%
YTD: 7.08%
Company Details
Employees: 295
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.